Results 141 to 150 of about 17,462,775 (406)

Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors – a biomarker analysis of the ALICE and ICON trials

open access: yesMolecular Oncology, EarlyView.
In this explorative biomarker analysis, we assessed serial sampling of circulating tumor cells (CTCs) with CellSearch in two randomized trials testing immune checkpoint inhibitors (ICIs) in metastatic breast cancer. Our data demonstrate a prognostic potential of CTCs, most apparent 4 weeks into ICI therapy.
Nikolai Kragøe Andresen   +13 more
wiley   +1 more source

Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies

open access: yesStem Cell Research & Therapy, 2019
Multipotent mesenchymal stromal cells (MSC) have been widely explored for cell-based therapy of immune-mediated, inflammatory, and degenerative diseases, due to their immunosuppressive, immunomodulatory, and regenerative potentials.
Nádia de Cássia Noronha   +7 more
doaj   +1 more source

A model for red blood cells in simulations of large-scale blood flows [PDF]

open access: yesarXiv, 2011
Red blood cells (RBCs) are an essential component of blood. A method to include the particulate nature of blood is introduced here with the goal of studying circulation in large-scale realistic vessels. The method uses a combination of the Lattice Boltzmann method (LBM) to account for the plasma motion, and a modified Molecular Dynamics scheme for the ...
arxiv  

Multifactorial analysis of human blood cell responses to clinical total body irradiation [PDF]

open access: yes, 1972
Multiple regression analysis techniques are used to study the effects of therapeutic radiation exposure, number of fractions, and time on such quantal responses as tumor control and skin injury.
Lushbaugh, C. C.   +2 more
core   +1 more source

Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients

open access: yesMolecular Oncology, EarlyView.
Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha   +6 more
wiley   +1 more source

Correction to: Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies

open access: yesStem Cell Research & Therapy, 2019
The original article [1] contained an error in the presentation of the first author’s name, Nádia de Cássia Noronha. This has now been corrected.
Nádia de Cássia Noronha   +7 more
doaj   +1 more source

Mathematical modeling of blood flow through arterial bifurcation [PDF]

open access: yesarXiv, 2020
The blood vascular system consists of blood vessels such as arteries, arterioles, capillaries and veins that convey blood throughout the body. The pressure difference which exists between the ends of the vessels provides the living force required to the flow of blood.
arxiv  

A comparative study of circulating tumor cell isolation and enumeration technologies in lung cancer

open access: yesMolecular Oncology, EarlyView.
Lung cancer cells were spiked into donor blood to evaluate the recovery rates of the following circulating tumor cell (CTC) enrichment technologies: CellMag™, EasySep™, RosetteSep™, Parsortix® PR1, and Parsortix® Prototype systems. Each method's advantages and disadvantages are described.
Volga M Saini   +11 more
wiley   +1 more source

High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors.

open access: yesBlood, 2013
Red blood cell (RBC) transfusion is a key treatment of patients with sickle cell disease (SCD) but remains complicated by RBC immunization. In the present study, we evaluated the effects of antigen matching for Rh D, C, and E, and K and transfusion from ...
S. Chou   +5 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy